Bajaj HealthCare Share Price Today

Bajaj Healthcare 33rd AGM passes all 6 resolutions including ₹1.50 dividend

Bajaj Healthcare's 33rd AGM on September 21, 2026 passed all 6 resolutions with the requisite majority. Final dividend of ₹1.50 per equity share for FY26 was declared and approved. Total votes polled stood at 20,390,550, representing 60.5687% of outstanding shares. Reappointment of Pakshal Anil Jain drew the highest dissent at 2.7902% of votes polled. Voting results and scrutinizer's report submitted to stock exchanges on September 22, 2026.

Bajaj Healthcare sets Sept 14 record date for ₹1.50 final dividend

Bajaj Healthcare fixes September 14, 2026, as record date for ₹1.50 per share final dividend. FY26 revenue rises 12.6% YoY to ₹611.03 crore driven by strong overseas performance. Net profit drops 50.4% to ₹213.10 crore due to ₹332.47 crore one-time exceptional loss. EBITDA grows 9.9% to ₹111.95 crore while margin contracts 45 bps to 18.32%. Debt-equity ratio improves to 0.47 times from 0.51 times in prior year.

Bajaj Healthcare schedules 33rd AGM for September 21, 2026

Bajaj Healthcare schedules its 33rd AGM for September 21, 2026, at 3:00 pm via VC/OAVM. Remote e-voting opens on September 17, 2026, and closes on September 20, 2026. The record date for voting eligibility is September 14, 2026. AGM notices and FY26 annual reports were dispatched on August 29, 2026. Physical shareholders must update KYC details to receive electronic dividend payments.

Bajaj Healthcare files FY26 BRSR with energy, waste data

Bajaj Healthcare filed its FY26 BRSR covering six manufacturing sites. Turnover reached ₹611.03 crore with exports contributing 31%. Total energy consumption rose to 501,706 Giga Joules. Permanent employee turnover jumped to 33.39% from 3.9%. Hazardous waste accounted for 99% of total waste generated.

Bajaj Healthcare gets DCGI approval to launch Cenobamate in India

Bajaj Healthcare secured DCGI approval to manufacture and market Cenobamate API and tablets in six strengths, becoming the first Indian company to launch this antiseizure medication. The approval follows an SEC recommendation received in June 2026 and strengthens the company’s CNS portfolio. Management views this as a significant milestone for long-term growth in the epilepsy treatment segment.

Bajaj Healthcare guides 10-15% FY27 revenue growth on API strength

Bajaj Healthcare Limited posted a 15.8% increase in Q1FY27 PAT to ₹13.7 crore, fueled by a 27.1% surge in domestic API sales. Management guided for 10-15% revenue growth in FY27, highlighting strategic expansions in peptides and oncology.